bispecific therapeutics

Oncology

For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?

News

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc.

News

Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.